Effect of Olanzapine Treatment for 12 Months on Body Weight in Psychiatric Patients
Article Sidebar
Main Article Content
Abstract
Objective: To explore the body weight change in Thai psychiatric patients who received olanzapine continuously for 12 months. Methods: This descriptive study retrospectively collected data from Thai psychiatric patients who received olanzapine continuously for 12 months at Srithanya Hospital from January 1 of 2012 to December 31 of 2021. Weight and body mass index (BMI) were monitored five times, i.e., at 0, 3, 6, 9, and 12 months. Data were analyzed using repeated measure ANCOVA. Results: One hundred seventy-six patients receiving olanzapine had an average age of 50.28 ± 13.93 years with 51.1% being female, and a mean body mass index (BMI) of 24.28 ± 3.93 kg/m2. The participants receiving olanzapine showed significant differences in body weight at different times (P<0.001). Body weight tended to increase over the time. The patients' average body weight increased approximately 7 kg at 12 months. At the twelfth month, the prevalence of patients whose body weight changed more than 7%, considered as clinically significant increase of body weight, was 63.1%. The prevalence of obesity (BMI >= 25 kg/m2) increased to 65.9% from 39.8% at baseline. Conclusion: Patients receiving olanzapine for 12 months had an increased body weight and having a high prevalence of obesity throughout the treatment. Therefore, patients with olanzapine should be monitored monthly for their body weight in the first three months, then every three months. Advices on self-care should be given to patients for effective and safe use of medication.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
Holt RI, Peveler RC. Obesity, serious mental illness and antipsychotic drugs. Diabetes, Diabetes Obes Metab 2009; 11: 665-79.
Stierman B, Afful J, Carroll MD, Chen T-C, Davy O, Fink S, et al. National health and nutrition examina- tion survey 2017–March 2020 prepandemic data files development of files and prevalence estimates for selected health outcomes [online]. 2021 [cited Sep 15, 2021]. Available from: stacks.cdc.gov/view/c dc/106273
Aekplakorn W, Puckcharern H, Satheannoppakao W. Health status. Thai national health examination survey, NHES VI. Bangkok: Asorn Graphic and Design; 2021. p. 169-73.
Tek C, Kucukgoncu S, Guloksuz S, Woods SW, Srihari VH, Annamalai A. Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications. Early Interv Psychiatry. 2016; 10: 193-202.
Bak M, Fransen A, Janssen J, van Os J, Drukker M. Almost all antipsychotics result in weight gain: a meta-analysis. PloS one. 2014; 9: e94112.
Wongpakaran R, Boonlue T. Psychotropic drugs induced weight gain. Srinagarind Medical Journal. 2015; 3: 311-18.
Lotrakul M, Prachasan T, Tantrarungroj T, Sukanich P, Saengchanchai P, Itthasakul P, et al. Clinical use of psychiatric drugs Bangkok: Beyond Enterprise; 2017.
Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Aru muham A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregu- lation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020; 7: 64-77.
Nasrallah H. Atypical antipsychotic-induced metabo- lic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008; 13: 27-35.
Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment pharmacological mecha- nisms. Pharmacol Ther. 2010; 125: 169-79.
Roerig JL, Steffen KJ, Mitchell JE. Atypical antipsychotic-induced weight gain: insights into mechanisms of action. CNS Drugs. 2011; 25: 1035-59.
Weir CB, Jan A. BMI classification percentile and cut off points [online]. 2019 [cited Sep 15, 2021]. Available from: www.ncbi.nlm.nih.gov/books/NBK54 1070/
Haddad P. Weight change with atypical antipsy- chotics in the treatment of schizophrenia. J Psycho pharmacol. 2005; 19: 16-27.
Sachs GS, Guille C. Weight gain associated with use of psychotropic medications. J Clin Psychiatry. 1999; 60 Suppl 21:16-9.
Bushe CJ, Slooff CJ, Haddad PM, Karagianis JL. Weight change by baseline BMI from three-year observational data: findings from the worldwide schizophrenia outpatient health outcomes database. J Psychopharmacol. 2013; 27: 358-65.
Allison DB, Mentore JL, Heo M, Chandler LP, Cappel leri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999; 156: 1686-96.
Bushe CJ, Slooff CJ, Haddad PM, Karagianis JL. Weight change from 3-year observational data: findings from the worldwide schizophrenia outpatient health outcomes database. J Clin Psychiatry. 2012; 73: 749-55.
Bazo-Alvarez JC, Morris TP, Carpenter JR, Hayes JF, Petersen I. Effects of long-term antipsychotics treatment on body weight: a population-based cohort study. J Psychopharmacol. 2020; 34: 79-85.
Kinon BJ, Basson BR, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry. 2001; 62: 92-100.
Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnor- malities: a five-year naturalistic study. Am J Psy- chiatry. 2000; 157: 975-81.
Novick D, Haro JM, Perrin E, Suarez D, Texeira JM. Tolerability of outpatient antipsychotic treatment: 36-month results from the European schizophrenia outpatient health outcomes (SOHO) study. Eur Neuropsychopharmacol. 2009; 19: 542-50.
Lee S-Y, Park M-H, Patkar AA, Pae C-U. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone. Prog Neuropsychopharmacol Biol Psy- chiatry. 2011; 35: 490-96.
Kryzhanovskaya LA, Xu W, Millen BA, Acharya N, Jen KY, Osuntokun O. Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olan- zapine. J Child Adolesc Psychopharmacol. 2012; 22: 157-65.
Kang H. Sample size determination and power analysis using the G* Power software. J Educ Eval Health Prof. 2021;18:17. doi: 10.3352/jeehp.2021.18 .17.
WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004; 363: 157-63.
Doane MJ, Bessonova L, Friedler HS, Mortimer KM, Cheng H, Brecht T, et al. Weight gain and comorbi- dities associated with oral second-generation anti- psychotics: analysis of real-world data for patients with schizophrenia or bipolar I disorder. BMC Psychiatry. 2022; 22: 1-12.
Mizuno Y, Suzuki T, Nakagawa A, Yoshida K, Mimura M, Fleischhacker WW, et al. Pharmaco logical strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizo phrenia: a systematic review and meta-analysis. Schizophr Bull. 2014; 40: 1385-403.
Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry. 2010; 71: 1259-72.
Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Weight gain and serum leptin levels in patients on lithium treatment. Neuropsychobiology. 2002; 46: 67-9.
Biton V, Mirza W, Montouris G, Vuong A, Hammer AE, Barrett PS. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology. 2001; 56: 172-77.
Ringen PA, Engh JA, Birkenaes AB, Dieset I, Andreassen OA. Increased mortality in schizophre- nia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and inter ventions. Front Psychiatry. 2014; 5: 137.
American Diabetes Association, American Psychia tric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004; 27: 596-601. doi: 10.2337/diacare.27.2.596.
